18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection is a phase 2, interventional study registered as NCT06503146 by National Cancer Institute (NCI), with a registry enrolment figure of 320 participants, started 2025-09-09 and due to reach its primary completion in 2028-06-01. Interventions recorded: [18F]FAPI-74; [18F]FDG. Conditions listed: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma; Pheochromocytoma/Paraganglioma (PPGL); Pancreatic Ductal Adenocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Gastric Cancer; Cholangiocarcinoma; Bladder Cancer. Primary outcome: Mean number of lesions. Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, bladder cancer, ovarian cancer, pheochromocytoma/paraganglioma (PPGL), small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancer (EP-NEC), mesothelioma ". Sites: United States. No results are recorded here; the registry entry is the source.